Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ. Press MF, et al. Among authors: buyse m. Mol Cancer Ther. 2017 Jan;16(1):228-238. doi: 10.1158/1535-7163.MCT-15-0887. Epub 2016 Nov 3. Mol Cancer Ther. 2017. PMID: 27811012 Clinical Trial.
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Valero V, et al. Among authors: buyse m. J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29. J Clin Oncol. 2011. PMID: 21115860 Clinical Trial.
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Press MF, et al. Among authors: buyse m. J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189395 Free PMC article. Clinical Trial.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. Among authors: buyse m. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A. Pestrin M, et al. Among authors: buyse m. Breast Cancer Res Treat. 2012 Jul;134(1):283-9. doi: 10.1007/s10549-012-2045-1. Epub 2012 Apr 4. Breast Cancer Res Treat. 2012. PMID: 22476856 Clinical Trial.
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.
Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. Hurvitz SA, et al. Among authors: buyse m. Clin Cancer Res. 2012 Jun 15;18(12):3478-86. doi: 10.1158/1078-0432.CCR-11-2294. Epub 2012 Apr 13. Clin Cancer Res. 2012. PMID: 22504044 Free PMC article. Clinical Trial.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Perez EA, et al. Among authors: buyse m. Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19. Breast Cancer Res Treat. 2013. PMID: 23420271 Free PMC article.
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
Paoletti X, Oba K, Bang YJ, Bleiberg H, Boku N, Bouché O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, Ohtsu A, Roth A, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Thuss-Patience P, Van Cutsem E, Burzykowski T, Buyse M; GASTRIC group. Paoletti X, et al. Among authors: buyse m. J Natl Cancer Inst. 2013 Nov 6;105(21):1667-70. doi: 10.1093/jnci/djt269. Epub 2013 Oct 9. J Natl Cancer Inst. 2013. PMID: 24108811 Free PMC article.
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.
Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T; GASTRIC group. Oba K, et al. Among authors: buyse m. J Natl Cancer Inst. 2013 Nov 6;105(21):1600-7. doi: 10.1093/jnci/djt270. Epub 2013 Oct 9. J Natl Cancer Inst. 2013. PMID: 24108812 Free PMC article. Review.
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Shi Q, et al. Among authors: buyse m. J Clin Oncol. 2015 Jan 1;33(1):22-8. doi: 10.1200/JCO.2014.56.5887. Epub 2014 Nov 10. J Clin Oncol. 2015. PMID: 25385741 Free PMC article.
470 results